COMBACTE-CDI 24/04/2017 Participants Participant No Participant - PowerPoint PPT Presentation

Clostridium difficile Infections COMBACTE-CDI 24/04/2017

Participants Participant No Participant organisation name Country 1 University Medical Center Utrecht (UMCU) the (Coordinator) Netherlands 2 (Co-leader) University of Leeds (UL) United Kingdom 3 Leiden University Medical Center (LUMC) the Netherlands 4 National Laboratory for Health, Environment and Food Slovenia (NLZOH) 5 Universitätsklinikum Köln (UKK) Germany 6 University of Antwerp (UA) Belgium 7 National Institute for Infectious Diseases “Lazzaro Italy Spallanzani” Rome (INMI) 8 Eberhard Karls University of Tubingen (EKUT) Germany 9 Pfizer (PFZ) Uniter Kingdom 10 GlaxoSmithKline Biologicals (GSKBio) Belgium 11 bioMérieux (BM) France 12 AstraZeneca/MedImmune (AZ/MI) United States 13 Astellas (AST) United Kingdom 14 Sanofi Pasteur (SP) France 15 Da Volterra (DAV) France

COMBACTE-CDI project structure 24/04/2017

ECDIS-Net COMBACTE EUCLID CLIN-Net Network COMBACTE EPI- COMBACTE Net LAB-Net Hospital identified that tests community and in-patient samples Sample days selected All networks will collaboratively identify hospitals of interest Hospitals will be selected from North, South, East and West Europe 24/04/2017

ECDIS-Net COMBACTE EUCLID CLIN-Net Network COMBACTE EPI- COMBACTE Net LAB-Net Hospital identified that tests community and in-patient samples Sample days selected Community Sent to ECL for Samples collected ‘optimal’ testing (missing cases Hospital samples found) collected O1.1 Samples collected on test days (regardless of test requested) will be tested at a European central laboratory using recommended ‘optimal’ testing methodology to find true burden of CDI 24/04/2017

ECDIS-Net COMBACTE EUCLID CLIN-Net Network COMBACTE EPI- COMBACTE Net LAB-Net Hospital identified that tests community and in-patient samples Sample days selected Community Sent to ECL for Samples collected ‘optimal’ testing (missing cases Hospital samples found) collected O1.1 Strains sent for Isolates of C. difficile analysis O1.2 identified from the community and hospital samples will be sent for further analysis; including PCR- ribotyping and whole genome sequencing to identify factors that may be driving clustering of strains 24/04/2017

ECDIS-Net COMBACTE EUCLID CLIN-Net Network COMBACTE EPI- COMBACTE Net LAB-Net Hospital identified that tests community and in-patient samples Sample days selected Community Retrospective Sent to ECL for Samples collected data collection ‘optimal’ testing for risk factors (missing cases Hospital samples O1.4 found) collected O1.1 Strains sent for analysis O1.2 Clinical report form Follow up for 6 deigned to capture data months; outcome for risk factor analysis and data outcome data on all O1.3 positive (ECL defined) and a proportion of negative samples; completed 6 months after sample collection date 24/04/2017

ECDIS-Net COMBACTE EUCLID CLIN-Net Network COMBACTE EPI- COMBACTE Net LAB-Net Hospital identified that tests community and in-patient samples Sample days selected Community Retrospective Sent to ECL for Samples collected data collection ‘optimal’ testing for risk factors (missing cases Hospital samples O1.4 found) collected O1.1 Strains sent for analysis Transmission O1.2 modelling O1.5 Follow up for 6 months; outcome data O1.3 All data collected from O1.1, 1.2, 1.3 and 1.4 will be used for the transmission modelling analysis in O1.5 24/04/2017

ECDIS-Net COMBACTE EUCLID CLIN-Net Network COMBACTE EPI- COMBACTE Net LAB-Net Hospital identified that tests community Questionnaire for and in-patient hospital/laboratory; samples Provides data for O2.1, 2.2, 2.3, 2.4 Sample days selected Community Retrospective Sent to ECL for Samples collected data collection ‘optimal’ testing for risk factors (missing cases Hospital samples O1.4 found) collected O1.1 Strains sent for analysis Transmission O1.2 modelling O1.5 Follow up for 6 months; outcome data Hospitals will complete a questionnaire to O1.3 enhance current ECDC data regarding ; T esting policy and methodology Surveillance practices Guidelines available and compliance ‘severe’ patient stratification. Data uploaded to central website 24/04/2017 Provides data for O2.1, 2.2, 2.3, 2.4

ECDIS-Net COMBACTE EUCLID CLIN-Net Network COMBACTE EPI- COMBACTE Net LAB-Net Hospital identified that tests community Questionnaire for and in-patient hospital/laboratory; samples Provides data for O2.1, 2.2, 2.3, 2.4 Sample days selected Community Retrospective Sent to ECL for Samples collected data collection ‘optimal’ testing for risk factors (missing cases Hospital samples O1.4 found) collected O1.1 Strains sent for analysis Transmission O1.2 modelling O1.5 Follow up for 6 months; outcome data O1.3 All data from previous objectives in WP1 and WP2 Costs and cost effectiveness will be fed into the cost O2.5, 2.6 effectiveness objectives in 24/04/2017 2.5 and 2.6

ECDIS-Net COMBACTE EUCLID CLIN-Net Network COMBACTE EPI- COMBACTE Net LAB-Net Hospital identified that tests community Questionnaire for and in-patient hospital/laboratory; samples Provides data for O2.1, 2.2, 2.3, 2.4 Sample days selected Community Retrospective Sent to ECL for Samples collected data collection ‘optimal’ testing for risk factors (missing cases Hospital samples O1.4 found) collected O1.1 Strains sent for analysis Transmission O1.2 modelling O1.5 Follow up for 6 months; outcome data O1.3 This synergistic approach Costs and cost effectiveness will enable completion of all O2.5, 2.6 objectives from WP1 and WP2 24/04/2017

Acknowledgements  Marc Bonten  Jovanka Bestebroer  Kerrie Davies  Georgina Davies  All the COMBACTE CDI team for all the hard work done … and still to be done  24/04/2017